



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Saeed R. Khan, et al.) Group Art Unit: TBA
Serial No.: 10/627,991) Examiner: TBA
Filed: July 28, 2003) Attorney Docket No. 001107.00371
For: DESIGN AND SYNTHESIS OF RENAL)
DIPEPTIDASE INHIBITORS)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:


Submitted herewith is one (1) sheet of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.

Respectfully submitted,


BANNER & WITCOFF, LTD.

By:


Sarah A. Kagan
Registration No. 32,141

Dated: August 11, 2003

Banner & Witcoff, Ltd.
Customer No. 22907



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				C m pl te if Kn wn	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/627,991
(use as many sheets as necessary)				Filing Date	July 28, 2003
				First Named Inventor	Saeed R. Khan
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	1	of	1	Attorney Docket Number	001107.00371

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		BUCKHAULTS P., et al., "Secreted and cell surface genes expressed in benign and malignant colorectal tumors", <i>Cancer Research</i> , (2001) Vol. 61, pp. 6996-7001			
		PARSONS W., et al., "A new class of potent, slowly reversible dehydropeptidase inhibitors", <i>Biochemical International</i> , (1991) Vol. 23, pp. 1107-1115			
		HARPER C., et al., "Renal Dipeptidase: Localization and Inhibition", <i>Biochimica Et Biophysica Acta</i> , (1971) Vol. 242, pp. 446-458			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231